Rosacea relief? new combo therapy targets redness and flushing
NCT ID NCT07343635
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a mix of anti-inflammatory cream (Hirudoid), yellow light therapy, and oral drugs (tofacitinib and doxycycline) can reduce redness and flushing in people with mild to moderate rosacea. About 186 Chinese adults will receive either this combo or a standard treatment for 12 weeks. The goal is to see if the new approach leads to clearer skin and better quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Doxycycline, Hydroxychloroquine, Tofacitinib, Hirudoid cream, and yellow light therapy
- What this could lead to
- If successful, this combination could offer a more effective way to control redness and flushing in rosacea patients.
- What could go wrong
- This is an early-stage study with no phase, so results are uncertain. The combination may cause side effects or not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHEMATOTELANGIECTATIC ROSACEA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGYiwu, Zhejiang, 322000, China